A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics

Psoriatic Arthritis In Skin Clinics (PARIS) Study. A Multicentre, Observational, Descriptive Cross-Cultural Validation Study and Estimate of the Proportion of Patients With Psoriatic Arthritis Among Psoriasis Patients Attending Dermatology Clinics Selected for This Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02470481

Acronym

PARIS

Enrollment

250

Registered

2015-06-12

Start date

2015-03-31

Completion date

2016-07-31

Last updated

2016-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Keywords

Psoriatic arthritis

Brief summary

The purpose of this study is to conduct full psychometric testing of the Early Arthritis for Psoriatic Patients (EARP) questionnaire in Australian, Korean and Chinese populations

Detailed description

This is a multicentre, observational, descriptive estimate of the proportion of participants with psoriatic arthritis among psoriasis participants attending dermatology clinics selected for this study. In addition, this study will involve full psychometric assessment of the Early psoriatic screening questionnaire (EARP) questionnaire with the aim of identifying and appropriately referring participants to a rheumatologist for review if their EARP score is 3 or greater at Screening (i.e. \>= 3 at Visit 1).

Interventions

OTHERNo Intervention

This is an obervational study

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patient must be a man or woman aged 18 to 65 years of age, inclusive * The patient must have an established diagnosis of psoriasis (based upon clinical evidence, and documented medical history \[19\]) * The patient must be able to read and write in the target language (English, Mandarin or Korean; or other relevant target languages) * Each patient must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study

Exclusion criteria

* An established diagnosis of psoriatic arthritis * Ever have received systemic treatment with a disease modifying antirheumatic drug (DMARD) for arthritis or spondylitis (inflammatory back pain) * Ever have received systemic treatment with a biologic therapy for psoriasis (including infliximab, golimumab, ustekinumab, adalimumab or etanercept) * A history of employment in or are currently employed in the healthcare industry; or * Participated in the translation and linguistic validation of the EARP questionnaire

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants With Psoriatic Arthritis	Baseline up to Day 28	Percentage of participants with psoriatic arthritis will be assessed using formula: Number of participants diagnosed with psoriatic arthritis divided by total number of participants with psoriasis attending the dermatology clinic.

Countries

Australia, China, South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026